Home/Filings/4/0000899243-21-026769
4//SEC Filing

Bolzon Bradley J PhD 4

Accession 0000899243-21-026769

CIK 0001826457other

Filed

Jun 29, 8:00 PM ET

Accepted

Jun 30, 5:05 PM ET

Size

19.4 KB

Accession

0000899243-21-026769

Insider Transaction Report

Form 4
Period: 2021-06-28
Bolzon Bradley J PhD
Director10% Owner
Transactions
  • Conversion

    Series A convertible preferred stock

    2021-06-2820,004,2800 total(indirect: By Versant Capital VI, L.P.)
    Common Stock (5,666,131 underlying)
  • Conversion

    Series B convertible preferred stock

    2021-06-283,000,0000 total(indirect: By Versant Capital VI, L.P.)
    Common Stock (849,738 underlying)
  • Conversion

    Common Stock

    2021-06-28+1,940,0431,940,043 total(indirect: By Versant Vantage I, L.P.)
  • Conversion

    Common Stock

    2021-06-28+6,515,8696,799,115 total(indirect: By Versant Venture Capital VI, L.P.)
  • Conversion

    Series B convertible preferred stock

    2021-06-284,150,0000 total(indirect: By Versant Vantage I, L.P.)
    Common Stock (1,175,470 underlying)
  • Conversion

    Series C convertible preferred stock

    2021-06-282,699,3280 total(indirect: By Versant Vantage I, L.P.)
    Common Stock (764,573 underlying)
  • Purchase

    Common Stock

    2021-06-28$19.00/sh+157,895$3,000,0052,097,938 total(indirect: By Versant Vantage I, L.P.)
Footnotes (3)
  • [F1]Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
  • [F2]Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
  • [F3]Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

Issuer

Monte Rosa Therapeutics, Inc.

CIK 0001826457

Entity typeother

Related Parties

1
  • filerCIK 0001354345

Filing Metadata

Form type
4
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 5:05 PM ET
Size
19.4 KB